| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from hamster) |
| Target | PD-1, VEGF-A |
| Clinical data | |
| Other names | AK112 |
| Pharmacokinetic data | |
| Elimination half-life | 6-7 days |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso Biopharma, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy, [1] and is undergoing clinical trials elsewhere.
Ivonescimab prevents tumor proliferation and angiogenesis by inhibiting programmed cell death protein 1 and vascular endothelial growth factor A, respectively. [2]
Ivonescimab so far has only completed trials in Chinese patients, [3] and is currently undergoing phase III trials in the United States for the treatment of non-squamous non-small-cell lung cancer and advanced NSCLC. [4]
The initial success of ivonescimab in trials is compared to already-approved drugs such as Merck & Co.'s Keytruda (pembrolizumab); its success has been described as important for the pharmaceutical industry in China. [5]
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
